Despite these considerations, even the somewhat limited perfusion of Stat3-siRNA observed in our in vivo experiments with LPP therapy allowed to achieve impressive effects on tumor growth and overall survival, further supporting the suitability of STAT3 as an excellent target for GBM therapy. This evidence concerns the gene STAT3 and glioblastoma.